Learning Objectives

By the end of the review, attendees will be better equipped to:

  • Determine which patients with hematologic malignancy may benefit from specific targeted therapy

  • Recognize myriad of presentations of patients with hematologic illnesses

  • Identify higher-risk patients with hematologic malignancy and determine the best available therapies

  • Prescribe individualized plans for patients with hematologic malignancies based on specific disease characteristics (genetics, molecular markers, etc.)

  • Manage complications of hematologic malignancies in an outpatient setting

  • Familiarize health care practitioners with the latest updates as per clinical trial data in the proper diagnosis and treatment of benign hematologic diseases, such as sickle cell anemia, coagulopathies, and autoimmune hemolytic anemia

Continuing Education Credit


The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 


This course provides up to 6.0 continuing nursing education contact hours through the UCHealth Department of Professional Development.

UCHealth is approved as a provider of nursing continuing professional development by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

DISCLAIMER: Division of Hematology CE presentations are strictly for educational purposes only. Our main goal is to increase the knowledge and competence of those within the medical field to improve patient care. Presentors will not provide direct medical, consultation, diagnostic, or treatment advice to participants.